/
IRIX
$1.14+$0.01 (+0.44%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$19.7M
17M shares
52-week range
$0.87 – $1.65
34% from low
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.26%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-5.95
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $42.6M | $43.4M | $36.3M | $53.9M | $57.0M | $51.9M | $48.7M | $52.7M |
| Cost of revenue | $25.1M | $25.5M | $20.8M | $31.1M | $31.6M | $30.1M | $29.2M | $33.4M |
| Gross profit | $17.5M | $17.9M | $15.6M | $22.8M | $25.4M | $21.8M | $19.5M | $19.3M |
| Gross margin | 41.0% | 41.3% | 42.8% | 42.4% | 44.5% | 42.0% | 40.1% | 36.7% |
| R&D | $4.0M | $3.7M | $3.3M | $6.9M | $7.2M | $6.8M | $5.4M | $3.7M |
| Operating income | −$12.9M | −$9.0M | −$6.6M | −$7.5M | −$7.5M | −$10.0M | −$8.3M | −$2.6M |
| EBITDA | −$12.1M | −$8.3M | −$6.1M | −$4.4M | −$6.1M | −$7.4M | −$7.4M | −$2.8M |
| Net income | −$12.8M | −$8.8M | −$6.3M | −$5.2M | −$7.5M | −$9.6M | −$8.9M | −$4.4M |
| Net margin | -30.1% | -20.3% | -17.4% | -9.7% | -13.2% | -18.5% | -18.3% | -8.4% |
| EPS (diluted) | -1.05 | -0.64 | -0.46 | -0.34 | -0.47 | -0.59 | -0.54 | -0.26 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $53M | $-0.05 | $-0.05–$-0.05 | 1 |
| 2028 | $57M | $0.02 | $0.02–$0.02 | 1 |
| 2029 | $60M | $0.07 | $0.07–$0.07 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Iridex Corp
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
www.iridex.com- Employees
- 108
- IPO / List date
- Feb 16, 1996
- HQ
- MOUNTAIN VIEW, CA
Held by traders on TradeandTell
No one on the platform currently holds IRIX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 396,627 | $400.6K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IRIX yet.
